Association of vitamin D receptor gene polymorphisms with osteosarcoma risk and prognosis

Nilgun Kurucu¹⁎, Gurses Şahinb, Neriman Saric, Serdar Ceylanerd, İnci Ergurhan İllanca

¹ Department of Pediatric Oncology, Hacettepe University Faculty of Medicine, Sihhiye, Ankara, Turkey
² Dr. Sami Ulas Woman and Child Health Training and Research Hospital, Sağlık Bilimleri University, Ankara, Turkey
³ A.Y. Ankara Oncology Training and Research Hospital, Sağlık Bilimleri University, Ankara, Turkey
⁴ Intergen Genetic Centre, Ankara, Turkey

Abstract

Objective: Through its receptor (VDR), vitamin D₃ plays an important role in a wide variety of cellular processes. Polymorphisms in VDR gene have been linked to risk of various cancers and their prognoses. We conducted a case-control study to analyze the relationship of VDR gene polymorphisms with the occurrence and prognosis of osteosarcoma.

Methods: Fifty-eight osteosarcoma patients and 75 healthy controls were included in the study. Single nucleotide change polymorphisms (SNPs) in Cdx2, FokI, BsmI, ApaI and TaqI regions of VDR gene were examined with SNaPshot mini-sequencing technique. Allele and genotype frequencies in patients and controls were compared. The association of polymorphic genotypes with osteosarcoma was evaluated. The relationship of the presence of polymorphism to prognostic parameters and survival rates were also analyzed.

Results: Allele and genotype frequencies of Cdx2, FokI, BsmI, ApaI and TaqI regions in VDR gene were found to be similar in patients and controls. Polymorphisms in these regions were not associated with osteosarcoma risk. In patients having Cdx2 polymorphic allele, tumor volume was greater (p=0.041), metastasis was more common (p=0.042) and histopathological response to chemotherapy was worse (p=0.044). Good histopathological response was significantly higher in patients with BsmI homozygous polymorphism (p=0.037). In the presence of heterozygous Cdx2 and homozygous a higher three-year overall survival rate was found, while there was a higher event-free survival rate in patients with ApaI polymorphisms.

Conclusion: Our results suggested that although polymorphisms of VDR gene are not related to the development of osteosarcoma, they may be important for prognosis. Understanding the effect of VDR polymorphisms on osteosarcoma will be important in identifying new prognostic parameters and new targets for treatment.

Keywords:
Osteosarcoma
Vitamin D₃
Vitamin D receptor
Polymorphism

1. Introduction

The active form of vitamin D, 1,25 dihydroxy vitamin D₃ (vitamin D₃), plays an important role in calcium homeostasis and bone metabolism [1]. It is clear that it also has effects on a wide range of fundamental biological functions such as cell cycle regulation, differentiation and immunomodulation. The molecular mechanisms of these effects are complex. The influence of vitamin D₃ upon the expression of several transcription factors, cell cycle arrest proteins and growth factors may explain these complex mechanisms [1,2]. Most of the biological activity of vitamin D₃ is mediated through its nuclear receptor (VDR). VDR binds to vitamin D₃ with high affinity and controls the expression of target genes by acting as a ligand activated transcription factor [2].

Changes in level of vitamin D₃ and variations in VDR have been linked to a variety of diseases such as recurrent infections, osteoarthritis, osteoporosis, diabetes mellitus, and cardiovascular and autoimmune diseases [3,4]. Moreover, strong epidemiological evidence showed a relationship between vitamin D₃ deficiency and several types of cancer [5,6]. Numerous genetic and biological studies established that alterations in VDR gene are also associated with cancer. Single nucleotide changes causing variations in DNA sequence, referred to as polymorphism, occur in more than 1% of the population. Single nucleotide change polymorphisms (SNPs) in VDR gene have been connected to the risk of various cancers such as breast, prostate and colon carcinomas and their prognoses [4,7]. However, there are only a few studies evaluating the relationship between malignant bone tumors and the polymorphisms in VDR gene which is a key regulator of bone
health. We conducted a case-control study to analyze the relationship of SNPs in VDR gene with the risk of occurrence and the prognosis of osteosarcoma.

2. Material and methods

Fifty-eight pediatric osteosarcoma patients diagnosed in the Ankara Oncology Research and Training Hospital were included in the study. The age and gender of patients, the location, size and histopathological subtype of the tumor, response to treatment and survival times were recorded. As a control group, 75 age- and sex-matched children, who were admitted to hospital for various reasons other than chronic diseases or malignancies, were also included in the study. After informed consent had been obtained from all the families, a 2 ml venous blood sample was drawn from patients and controls. Samples were stored at −20 °C in EDTA-containing tubes for future analysis.

After the thawing of blood samples, nucleic acid isolation was performed via the spin-colon method (Qiagen®, QIAamp DNA Mini Kit). Cdx2, FokI, BsmI, ApaI and TaqI regions of VDR gene were amplified. Multiplex PCR was performed with the in-house designed primers. PCR mixture: 10 ng of genomic DNA was set to be 0.1 mmol/L of each primer (forward and reverse), 0.4 mmol/L dNTP, 3.0 mmol/L MgCl2, 10x PCR buffer, and 1 U Taq polymerase and final volume of 20 µL. Post-PCR purification was performed with 5 µL SNaPshot ready reaction mix (Applied Biosystems, Inc.), 2 µl purification product, 0.4 µM primer (for each parameter) in 10 µl reaction volume. After the Minisequencing reaction, 10 µl of final volume 1 was treated with SAP for 60 min at 37 °C. Enzyme inactivation was then performed at 75 °C for 15 min. Minisequencing products (0.5 µl) were mixed with 9 µl of Hi-Di formamide and 0.5 µl GeneScan-120 LIZ size standard (Applied Biosystems) and denatured at 95 °C for 5 min. Fluorescent labeled products were analyzed with an ABI 3130 Genetic Analyzer (Applied Biosystems). The obtained data were evaluated with GeneMapper 4.0 software (Applied Biosystems Co. Ltd., USA).

Allele and genotype frequencies of patients and control groups were identified and compared with the chi-square test. Association of polymorphic genotypes with osteosarcoma was evaluated by using Mantel–Haenszel test and odds ratios were calculated with a 95% confidence interval. The relationship between the prognostic parameters and the presence of polymorphisms were analyzed with chi-square test. Survival rates were calculated with Kaplan–Meier test. The relationship of the presence to polymorphisms and survival rates were analyzed with log-rank test.

3. Results

In the osteosarcoma group, there were 33 boys (56.8%) and 25 girls (43.2%) with a mean age of 12.45 ± 3.48 (4–18) years. Fifty-two percent of the control group was male (n=39) and 48% was female (n=36) and the mean age was 11.01 ± 3.95 (5–19) years. There were no clinical findings of hypovitaminosis D in neither patient nor the control group. Although vitamin D levels were not specifically measured, no laboratory evidence of hypovitaminosis D, such as hypocalemia, was also not present in the patient group.

Tumor locations were the lower extremities in 48 patients (82.8%), upper extremities in five (8.6%) and flat bones in five (8.6%). Histopathological subtypes were osteoblastic in 41 cases (70.7%), other types (chondroblastic, fibroblastic and small cell type) in seven (13.8%) and un-classified in nine (15.5%). Tumor volume was more than 200 mm³ in 20 patients (34.5%), less than 200 mm³ in 36 (62.1%) and un-determined in 2 (3.4%). Twelve patients (20.7%) had metastatic disease (6 lung, 4 lung&bone, 2 others) at diagnosis. Patients were treated with MAP protocol (methotrexate 12 gr/m², doxorubicin 2 × 30 mg/m², cisplatin 120 mg/m²). After chemotherapy the percentage of necrosis in tumor tissue was higher than 90% in 23 cases (39.7%), less than 90% in 17 (29.3%) and unknown in 18 (31%).

Allele frequency of all studied regions in patients with osteosarcoma and the control group were similar (Table 1). In osteosarcoma patients, the frequency of homozygous and heterozygous polymorphisms were 6.9% and 18%, respectively in FokI region, 12.1% and 60.3% in BsmI region, 32.8% and 53% in Apa I region, 37.9% and 56.9% in TaqI region, and 3.4% and 34.5% in Cdx2 region. The differences in genotype frequencies of the patient and control group were not significant (Table 2). The presence of heterozygous polymorphism in BsmI (OR:1.48), ApaI (OR:1.46) and TaqI (OR:1.35) and Cdx2 (OR:1.12) regions seemed to increase osteosarcoma risk. However, the increased odds did not reach statistical significance since the 95% confidence interval spanned 1.0 (Table 3).

The relationship of SNPs in VDR gene to the prognosis of disease were also analyzed. Tumor volume was more than 200 mm³ in 81.8% of patients who carried the polymorphic Cdx2 allele while this ratio was 55.5% in patients with wild type genotype (p=0.041). Frequency of metastatic disease was more common in patients who had the Cdx2 polymorphic allele than those having the wild type genotype (36.6% vs 11.1%, p=0.042). Furthermore, good histopathological response to chemotherapy (>90%) was obtained in 43.8% of patients with polymorphic Cdx2, while this ratio reached 76.2% in patients with wild type Cdx2 (p=0.044). More than 90% necrosis was determined in all patients with BsmI homozygous polymorphic genotype, but this ratio was 54.8% in patients with wild type BsmI (p=0.037). Patients were followed for a median of 49.5 months after treatment. The three-year overall survival rate was lower in patients with heterozygous polymorphic Cdx2 than in those with wild type although the difference was not statistically significant (73.3% and 92.6%, p=0.06). The three-year event-free survival rate was significantly higher in the presence of homozygous polymorphic ApaI than others (87.2% vs 51.2% p=0.015). The other polymorphic genotypes had no effect on survival.

4. Discussion

In-vitro and in-vivo studies have shown that vitamin D₃ exerts an inhibitory effect on the development and progression of cancer. Various cellular functions of vitamin D₃, including inhibition of proliferation, induction of apoptosis and differentiation, modulation of growth factor-mediated signaling and inhibition of angiogenesis play a role in its anticancer effects [2,5,6]. Binding of the vitamin to VDR and its nuclear activation are necessary for the biological effects to occur. VDR, which can be categorized as a ligand activated transcription factor, is a member of the nuclear receptors superfamily of steroid hormones and is present in more than 30 tissues and organs [3,4,8]. VDR expression has also been determined in many types of cancer cells such as breast, prostate, pancreas, colon, bladder, cervix, melanoma, leukemia and
Table 2

| Polymorphism Frequency in Cdx2, FokI, BsmI, ApaI, TaqI Region of VDR Gene in Patients and Controls |
|---------------------------------------------------------------|
| **Polymorphism** | **Patients** | **Controls** | **P** |
| Cdx2 polymorphism | Homozygous (GG) | 63.9% | 60.3% | >0.05 |
|                  | Heterozygous (Gg) | 36.1% | 39.7% | >0.05 |
| FokI polymorphism | Homozygous (FF) | 56.9% | 48.3% | >0.05 |
|                  | Heterozygous (Ff) | 43.1% | 51.7% | >0.05 |
| BsmI polymorphism | Homozygous (BB) | 13.8% | 21.0% | >0.05 |
|                  | Heterozygous (Bb) | 86.2% | 79.0% | >0.05 |
| ApaI polymorphism | Homozygous (AA) | 34.5% | 4.0% | >0.05 |
|                  | Heterozygous (Ab) | 32.0% | 96.0% | >0.05 |
| TaqI polymorphism | Homozygous (TT) | 69.3% | 50.7% | >0.05 |
|                  | Heterozygous (Tt) | 30.7% | 49.3% | >0.05 |

Polymorphisms in these regions may in different regions of VDR gene and its polymorphism may affect the occurrence, development and outcome of various adult cancers such as breast (FokI, BsmI, ApaI), prostate (FokI, BsmI, TaqI), skin (FokI, BsmI, TaqI), colorectal (FokI, BsmI), ovary (FokI, ApaI) and renal cell carcinomas (FokI, ApaI) have been reported [7,9,11,12]. However, different results were observed in some other case-control and cohort studies [9,12]. Several meta-analyses which were conducted to clarify the relationship between these polymorphisms and cancer showed that there is a significant increase in the malignant melanoma and breast cancer risk in FokI FF genotype, a significant increase in colorectal carcinoma risk in TaqI TT genotype. A significant increase in the risk of all cancers types in Cdx2 gg genotype, while a significant decrease was found in the development of cancer at any site [11-15]. Data indicating an association between VDR polymorphisms and cancer prognosis are strongest for breast cancer (BsmI, TaqI), prostate cancer (FokI), malignant melanoma (BsmI) and renal cell carcinoma (TaqI) [11-13].

There are several studies on the role of VDR gene polymorphisms in the occurrence and prognosis of pediatric cancers. Bienertova-Vasku et al. [16] investigated FokI, BsmI, TaqI, ApaI and Cdx2 polymorphisms of VDR gene in 111 pediatric cases with different types of malignant solid tumors. They observed that the polymorphic genotype in FoxI was weakly associated with a reduced risk of susceptibility to cancer. They found that the survival rate of patients carrying heterozygous SNPs in BsmI and TaqI regions were significantly worse than patients with homozygous genotypes [16]. Yilmaz et al. [17] reported that there was no relationship between polymorphisms in Taq1, Fok1 and Bsm1 regions and the occurrence of brain tumors in 32 children. Tekgündüz et al. [18] found no significant difference between the 95 pediatric Hodgkin’s lymphoma cases and controls in terms of Cdx2, Fok1, Bsm1, Apol and Taq1 polymorphisms. They concluded that VDR polymorphisms do not play a role in Hodgkin’s lymphoma development. Dawidowska et al. [19] observed that polymorphic variants of BsmI were significantly implicated in minimal residual disease on day 15 in pre-B cell ALL.

There is limited data linking VDR gene polymorphisms with osteosarcoma risk and prognosis. However, several experimental studies
showed the effect of vitamin D₃ and VDR interaction on various cellular processes in osteoblasts whose malignant transformation results in osteosarcoma. Antiproliferative, differentiating and proapoptotic effects of vitamin D₃ on osteoblasts have been reported. Vitamin D₃ has been shown to inhibit cell cycle progression at the G1 phase and to promote osteoblast differentiation [19,20]. It was shown that VDR was expressed in osteosarcoma cells derived from cell lines or animal tumors, which indicates that osteosarcoma cells recognize and potentially respond to vitamin D₃ [21,22]. There are experimental studies which demonstrated that vitamin D₃ inhibits proliferation and enhances differentiation in osteosarcoma cells as it does in osteoblasts. For instance, Thomson et al. [21] demonstrated that human osteosarcoma cell lines respond to vitamin D₃ by undergoing differentiation and apoptosis. Barroga et al. [23] reported that the stimulation of canine osteosarcoma cells with vitamin D₃ results in their differentiation to more mature cells that exhibit properties of functionally mature osteoblastic bone cells. Davies et al. [22] observed a negative correlation between VDR expression and Ki-67 proliferation indexes in canine osteosarcoma cells although there was no relationship with tumor grade, type or location. Gallagher et al. [24] showed the expression of VDR in human osteosarcoma tissues obtained from the tumors of primary or metastatic osteosarcoma. They did not find any relationship between VDR expression and tumor grade, type, location, patients’ age or sex. Wu et al. [25] observed that vitamin D₃ treatment reduced cell proliferation only in human osteosarcoma cells that express native levels of VDR protein. They also showed that anti-proliferative actions of vitamin D₃ involve VDR mediated activation of the MAPK pathway. Yang et al. [26] found that inhibition of Snail-1, which is overexpressed in osteosarcomas, could enhance anti-proliferative activity of vitamin D₃ by increasing the expression of VDR.

In the light of these data, we investigated the role of polymorphisms in FokI, BsmI, Apal, TaqI and Cdx2 regions of VDR gene in the development, prognostic parameters and outcomes of osteosarcoma. We could not find a significant association between these polymorphisms and osteosarcoma occurrence. In the literature, there were only two clinical studies evaluating the association between the occurrence of osteosarcoma and variations in VDR gene. Miller et al. [27] investigated the role of deletions, rearrangements and point mutations of VDR gene in a variety of cancers including 68 osteosarcoma cases. Only two alterations, one silent mutation in codon 79, and a base change in intron 3, were detected in two osteosarcoma samples. They concluded that changes in VDR gene do not play a role in the development of either osteosarcoma or other cancers studied. Ruza et al. [28] analyzed the frequency of the genotypes for the FokI, Apal and TaqI polymorphisms of VDR gene in Spanish osteosarcoma patients. They showed a significantly higher frequency of the Ff genotype for the Fok I polymorphism compared to controls. The odds ratio for this genotype was found to be 1.78 with an increased relative risk of 78% for heterozygous Ff carriers. However, in our study, no significant correlation was found between the risk of osteosarcoma and FokI polymorphism.

We also analyzed the relationship between the polymorphisms in VDR gene and prognostic parameters and survival rates. Larger than 200 mm³ tumor volume, presence of metastasis, and less than 90% necrosis in tumor tissue after chemotherapy are known to be related with worse prognoses in osteosarcoma [27]. We found that patients carrying the Cdx2 polymorphic allele have all three bad prognostic factors significantly more frequently. Furthermore, the three-year overall survival rate was lower in patients with the heterozygous polymorphic Cdx2 genotype. Although there were no studies in the literature which showed the effect of Cdx2 on the prognosis and outcome of cancers, meta-analyses suggested that the Cdx2 polymorphism significantly increased overall cancer risk [14,15].

In conclusion, our results suggested that polymorphisms of VDR gene are not related with the development of osteosarcoma, but that they, especially in Cdx2 region, may have a prognostic importance. Osteosarcoma is the most common malignant bone tumor in children and adolescents. At present, the survival rate of the disease has not exceeded 60–70% with the current managements [29]. Therefore, there is a need to identify novel therapeutic approaches to improve the outcome of disease. Understanding the effect of VDR polymorphisms on osteosarcoma prognosis will be important in this aspect, which may make it possible to determine new targets for treatment.

Conflict of interest statement
Authors have no conflicts of interest or financial support to declare.

Acknowledgment
This work was supported by the Turkish Pediatric Oncology Society (TPOG).

References
[1] P. Lips, Vitamin D physiology, Prog. Biophys. Mol. Biol. 92 (2006) 4–8.
[2] Y. Weisman, Non-classic unexpected functions of vitamin D, Pediatr. Endocrinol. Rev. 8 (2010) 103–107.
[3] A.G. Uitterlinden, Y. Fang, J.B.J. van Meurs, et al., Vitamin D receptor gene polymorphisms in relation to vitamin D related disease states, J. Steroid. Biochem. Mol. Biol. 89–90 (2004) 187–193.
[4] J.M. Valdivielso, E. Fernández, Vitamin D receptor polymorphisms and disease, Clinica Chimica Acta 371 (2006) 1–12.
[5] R. Bouillon, T. Moody, M. Sporn, et al., NIH deltanoids meeting on vitamin D and cancer: conclusion and strategic options, J. Steroid Biochem. Mol. Biol. 97 (2005) 3–5.
[6] J.C. Fleet, Molecular actions of vitamin D contributing to cancer prevention, Mol. Asp. Med. 29 (2008) 388–396.

Table 3
Polymorphism frequency in Cdx2, FokI, BsmI, Apal, TaqI region of VDR gene in patients and controls and association with osteosarcoma risk.

| VDR allele | Hasta | Control | OR | %95 CI | p |
|------------|-------|---------|----|-------|---|
| FokI       |       |         |    |       |   |
| Wild       | 36 (%62.0) | 37 (%49.3) | 1.68 | 0.83–3.37 | 0.14 |
| Heterozygous polymorphic | 18 (%31) | 32 (%42.7) | 0.60 | 0.29–1.24 | 0.17 |
| Homozygous polymorphic | 4 (%6.9) | 6 (%8.0) | 0.85 | 0.22–3.17 | 0.81 |
| BsmI       |       |         |    |       |   |
| Wild       | 16 (%27.6) | 28 (%37.3) | 0.63 | 0.30–1.34 | 0.23 |
| Heterozygous polymorphic | 35 (%60.3) | 38 (%50.7) | 1.48 | 0.74–2.96 | 0.26 |
| Homozygous polymorphic | 7 (%12.1) | 9 (%12.0) | 1.07 | 0.35–2.88 | 0.99 |
| Apal       |       |         |    |       |   |
| Wild       | 19 (%32.8) | 26 (%34.7) | 0.97 | 0.47–2.01 | 0.94 |
| Heterozygous polymorphic | 31 (%53.4) | 33 (%44.0) | 1.46 | 0.73–2.90 | 0.28 |
| Homozygous polymorphic | 8 (%13.8) | 16 (%21.3) | 0.59 | 2.23–1.49 | 0.26 |
| TaqI       |       |         |    |       |   |
| Wild       | 22 (%37.9) | 31 (%41.3) | 0.86 | 0.43–1.75 | 0.69 |
| Heterozygous polymorphic | 33 (%56.9) | 37 (%50.7) | 1.35 | 0.38–2.70 | 0.38 |
| Homozygous polymorphic | 3 (%5.2) | 7 (%9.3) | 0.53 | 0.13–2.14 | 0.36 |
| Cdx2       |       |         |    |       |   |
| Wild       | 36 (%62.1) | 48 (%64.0) | 0.92 | 0.45–1.87 | 0.82 |
| Heterozygous polymorphic | 20 (%34.5) | 24 (%32.0) | 1.12 | 0.54–2.31 | 0.76 |
| Homozygous polymorphic | 2 (%3.4) | 3 (%4.0) | 0.85 | 0.13–2.31 | 0.87 |
M.J. Campbell, D.L. Trump, Vitamin D receptor signaling and cancer, Endocrinol. Metab. Clin. North Am. 46 (2017) 1009–1038.

A.G. Uitterlinden, Y. Fang, B.J. Joyce, et al., Genetics and biology of vitamin D receptor gene polymorphisms, Gene 338 (2004) 143–156.

K. Köstner, N. Denzer, C.S.L. Müller, et al., The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature, Anticancer Res. 29 (2009) 3511–3536.

R.B. Bouillon, G. Carmeliet, L. Verlinden, et al., Vitamin D and human health: lessons from vitamin D receptor null mice, Endocr. Rev. 29 (2008) 726–776.

S. Raimondi, H. Johansson, P. Maisonneuve, et al., Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk, Carcinogenesis 29 (2008) 1847–1861.

R.B. Bouillon, G. Carmeliet, L. Verlinden, et al., Vitamin D and human health: lessons from vitamin D receptor null mice, Endocr. Rev. 29 (2008) 726–776.

S. Raimondi, H. Johansson, P. Maisonneuve, et al., Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk, Carcinogenesis 29 (2008) 1847–1861.

V. Rai, J. Abd, S. Agrawal, et al., Vitamin D receptor polymorphism and cancer: an update, Anticancer Res. 37 (2017) 3991–4003.

Z.M. Dai, Y.L. Fei, W.G. Zhang, et al., Association of vitamin D receptor Cdx2 polymorphism with cancer risk, Medicine 94 (2015) 1–8.

S. Davide, G. Patrizia, R. Sara, et al., Meta analysis on vitamin D receptor and cancer risk: focus on the role of Taq I, Apa I and Cdx2 polymorphisms, Eur. J. Cancer Prev. 25 (2016) 85–96.

J. Bienertova-Vasku, K. Drabova, F. Zlamal, et al., Pre-treatment VD levels and VDR receptors as potential predictors of occurrence and overall survival in pediatric patients with solid tumors—a single institution pilot study, Tumor Biol. 37 (2016) 9209–0219.

B. Yılmaz, G.A. Tokuc, A. Koç, et al., Investigation of vitamin D receptor gene polymorphism in pediatric patients with brain cancer, Indian J. Med. Pediatr. Oncol. 38 (2017) 128–132.

S.A. Tekgündüz, S. Yeşil, A.C. Ören, et al., Vitamin D receptor (VDR) polymorphisms in pediatric patients presenting with Hodgkin’s lymphoma, J. Pediatr. Hematol. Oncol. 39 (2017) e59–e61.

M. Dawidowska, M. Kosmalska, L. Selek, et al., Association of germline genetic variants in RFC, IL15 and VDR genes with minimal residual disease in pediatric B-cell precursor ALL, Sci. Rep. 6 (2016) 29427, https://doi.org/10.1038/srep29427.

S. Ryhanen, T. Jaaskelainen, J.T. Saarela, et al., Inhibition of proliferation and induction of differentiation of osteoblastic cells by a novel 1α25 (OH)2 vitamin D3 analog with extensively modified side chain, J. Cell Biochem. 70 (1998) 414–424.

L. Thomson, S. Wang, O. Tawfik, et al., Effect of hydroxyvitamin D3 and 1 α,25 dihydroxyvitamin D3 on differentiation and apoptosis of human osteosarcoma cell lines, J. Orthop. Res. 30 (2012) 831–844.

J. Davies, H. Heeb, R. Gari melia, et al., Vitamin D receptor, retinoid x receptor, ki-67, surviving, and ezrin expression in canine osteosarcoma, Vet. Med. Int. 2012 (2012) 761034, https://doi.org/10.1155/2012/761034.

E.P. Barroga, T. Kadosawa, M. Okumura, et al., Influence of vitamin D and retinoids on the induction of functional differentiation in vitro of canine osteosarcoma clonal cells, Vet. J. 159 (2000) 186–193.

R. Gallagher, J. Keightley, J. Pucel, et al., Clinicopathologic correlation of vitamin D receptor expression with retinoid X receptor and MIB-1 expression in primary and metastatic osteosarcoma, Ann. Diagn. Pathol. 16 (2012) 323–329.

W. Wu, X. Zhang, L.P. Zanello, 1 α 25 dihydroxyvitamin D3 antiproliferative actions involved vitamin D receptor mediated activation of MAPK pathways and AP-1/p21 (waf1) upregulation in human osteosarcoma, Cancer Lett. 254 (2007) 75–86.

H. Yang, Y. Zhang, Z. Zhou, et al., Snail-1 regulates VDR signaling and inhibits 1,25 (OH)2 vitamin D3 action osteosarcoma, Eur. J. Pharmacol. 670 (2011) 341–346.

C.W. Miller, R. Morosetti, M.J. Campbell, et al., Integrity of the 1α,25-dihydroxyvitamin D3 receptor in bone, lung, and other cancer, Mol. Carcinog. 19 (1997) 254–257.

E. Ruza, E. Sotillo, L. Sierrasemumaga, et al., Analysis of polymorphisms of the vitamin D receptor, estrogen receptor, and collagen I α1 genes and their relationship with height in children with bone, J. Pediatr. Hematol. Oncol. 25 (2003) 780–786.

J.C. Friebele, J. Peck, P. Xueliang, et al., Osteosarcoma: A meta-analysis and review of the literature, Am. J. Orthop. 44 (2015) 547–553.